The role of extreme phenotype selection studies in the identification of clinically relevant genotypes in cancer research

Cancer

Volumn 95, Issue 7, 2002, Pages 1605-1610

  Perez Gracia, Jose Luis ^a   Ruiz Ilundain, Maria Gloria ^b   Garcia Ribas, Ignacio ^a   Carrasco, Eva Maria ^a  

^a ELI LILLY AND COMPANY   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Genetics; Long term survivors; Neoplastic disease; Protective genetic alterations

Indexed keywords

ARTICLE; CANCER GENETICS; CANCER RESEARCH; CANCER RISK; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; NEOPLASMS; PEDIGREE; PHENOTYPE; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0036785454     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10877     Document Type: Article

References (51)

1. Todd JA. Interpretation of results from genetic studies of multifactorial diseases. Lancet. 1999;354:1516-000.
2. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233-1238.
3. Miller RW. Deaths from childhood cancer in sibs. N Engl J Med. 1968;279:122-126.
4. Li FP, Fraumeni JF Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst. 1969;43:1365-1373.
5. Benedict WF, Murphree AL, Banerjee A, Spina CA, Sparkes MC, Sparkes RS. Patient with 13 chromosome deletion: evidence that the retinoblastoma gene is a recessive cancer gene. Science. 1983;219:973-975.
6. Cavenee WK, Dryja TP, Phillips RA, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature. 1983;305:779-784.
7. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820-823.
8. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990; 250:1684-1689.
9. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest. 1988;81:47-51.
10. Van Kuilenburg AB, Vreken P, Abeling NG, et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet. 1999;104:1-9.
11. Van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6:4705-4712.
12. Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res. 2001;7:2832-2839.
13. Miyaji M, Ogoshi K, Kajiura Y, et al. [A case of advanced gastric cancer with liver metastasis with no recurrence and long survival.] Gan To Kagaku Ryoho. 1996;23:915-918.
14. Mura T, Bandou H, Nomura T, Watanabe K, Kobayashi T. [A resected case of advanced gastric cancer with complete remission of liver metastasis by chronic daily administration of oral etoposide and UFT.] Gan To Kagaku Ryoho. 1992;19:1071-1074.
15. Sasaki Y, Sasaki J, Ito T, Nehashi Y. [Complete response in a case of unresectable gastric cancer with a combination of tegafur, 5-fluorouracil and mitomycin C.] Gan To Kagaku Ryoho. 1988;15:2793-2795.
16. Mukai M, Tokunaga N, Yasuda S, et al. Long-term survival after immunochemotherapy for juvenile colon cancer with peritoneal dissemination: a case report. Oncol Rep. 2000;7:1343-1347.
17. Silberstein E, Walfisch S, Lupu L, Sztarkier I. Twelve-year survival after the diagnosis of locally advanced carcinoma of the pancreas: a case report. J Surg Oncol. 2000;75:142-145.
18. Dutcher JP, Wiernik PH. Long-term survival of a patient with multiple myeloma-a cure? A case report. Cancer. 1984;53:2069-2072.
19. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1986;4:702-709.
20. Satoh H, Ishikawa H, Yamashita YT, et al. Analysis of long-term survivors after platinum containing chemotherapy in advanced non-small cell lung cancer. Anticancer Res. 1998;18:1295-1298.
21. Sculier JP, Paesmans M, Libert P, et al. Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer. European Lung Cancer Working Party. Eur J Cancer. 1994;30:1342-1347.
22. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 correceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367-377.
23. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722-725.
24. Quillent C, Oberlin E, Braun J, et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet. 1998;351:14-18.
25. Rowland-Jones S, Sutton J, Ariyoshi K, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med. 1995;1:59-64.
26. Girelli D, Russo C, Ferraresi P, et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med. 2000;343:774-780.
27. Gambaro G, Anglani F, D'Angelo A. Association studies of genetic polymorphisms and complex disease. Lancet. 2000;355:308-311.
28. Yu Q, Geng Y, Sicinsky P. Specific protection against breast cancer by cyclin D1 ablation. Nature. 2001;411:1017-1021.
29. Sicinski P, Donaher JL, Parker SB, et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell. 1995;82:621-630.
30. Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 1995;9:2364-2372.
31. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res. 1997;57:5001-5003.
32. Schabath MB, Spitz MR, Zhang X, Delclos GL, Wu X. Genetic variants of myeloperoxidase and lung cancer risk. Carcinogenesis. 2000;21:1163-1166.
33. Le Marchand L, Seifried A, Lum A, Wilkens LR. Association of the myeloperoxidase-463 G→A polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prevent. 2000;9:181-184.
34. Cascorbi I, Henning S, Brockmoller J, et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant-463A of the myeloperoxidase gene. Cancer Res. 2000;60:644-649.
35. Chen H, Lum A, Seifried A, Wilkens LR, Le Marchand L. Association of the NAD(P)H:quinone oxidoreductase 609 C →T polymorphism with a decreased lung cancer risk. Cancer Res. 1999;59:3045-3048.
36. London SJ, Smart J, Daly AK. Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County. Lung Cancer. 2000;28:147-155.
37. Harth V, Donat S, Ko Y, Abel J, Vetter H, Bruning T. NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer. Arch Toxicol. 2000;73:528-531.
38. Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet. 1997;350:630-633.
39. Benhamou S, Reinikainen M, Bouchardy C, Dayer P, Hirvonen A. Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res. 1998;58:5291-5293.
40. Skibola CF, Smith MT, Kane E, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA. 1999;96:12810-12815.
41. Chen J, Giovanucci E, Kelsey K, et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal. cancer. Cancer Res. 1996;56:4862-4864.
42. Ma J, Stampfer MJ, Giovanucci E, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res. 1997;57:1098-1102.
43. Houlston RS. CYP1A1 polymorphisms and lung cancer risk: a meta-analysis. Pharmacogenetics. 2000;10:105-114.
44. Christensen PM, Gotzsche PC, Brosen K. The sparteine/ debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur J Clin Pharmacol. 1997;51:389-393.
45. Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics. 1998;8:227-238.
46. Milner BJ, Brown I, Gabra H, Kitchener HC, Parkin DE, Haites NE. A protective role for common p21WAF1/Cip1 polymorphisms in human ovarian cancer. Int J Oncol. 1999;15:117-119.
47. Houlston RS. Glutathione S-transferase M1 status and lung cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prevent. 1999;8:675-682.
48. Tokumoto H. Analysis of HLA-DRB1-related alleles in Japanese patients with lung cancer-relationship to genetic susceptibility and resistance to lung cancer. J Cancer Res Clin Oncol. 1998;124:511-516.
49. Ichimiya M, Muto M, Hamamoto Y, Ohmura A, Tateno H, Asagami C. Putative linkage between HLA class I polymorphism and the susceptibility to malignant melanoma. Australas J Dermatol. 1996;37(Suppl 1):S39.
50. Ozdemir E, Kakehi Y, Nakamura E, et al. HLA-DRB1*0101 and *0405 as protective alleles in Japanese patients with renal cell carcinoma. Cancer Res. 1997;57:742-746.
51. Dunning AM, Chiano M, Smith NR, et al. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet. 1997;6:285-289.